Expression of miR-634 in gastric carcinoma and its effects on proliferation, migration, and invasion of gastric cancer cells

Jiao Guo1, Chun-Dong Zhang1, Jia-Xiang An1, Yun-Yun Xiao2, Shuai Shao1, Nuo-Ming Zhou1 & Dong-Qiu Dai1,3

1Department of Gastrointestinal Surgery, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China
2Department of Obstetrics and Gynecology, the Shengjing Affiliated Hospital of China Medical University, Shenyang 110004, China
3Cancer Center, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China

Keywords
Gastric cancer, JAG1, MGC-803, miR-634, SGC-7901

Abstract
This study aims to observe the expression of microRNA (miR)-634 in different gastric cancer cell lines and tissues, and to study the effects of miR-634 on the proliferation, migration, and invasion of the gastric cancer cells. The miR-634 mimics and miR-634 inhibitors were transfected by lentivirus into human gastric cancer SGC-7901 and MGC-803 cells, and the miR-634 cells without transfection were used as the control group (NC group). The expression of miR-634 in the transfected cells was detected by qRT-PCR. Cell viability was measured by the CCK8 assay. The migration and invasion ability of the cells were detected by scratch assays and Transwell® chamber assays, respectively, and the luciferase assay verified the binding of miR-634 to the target gene JAG1. The expression level of miR-634 in gastric cancer tissues and cell lines was significantly lower than that in normal adjacent tissues and control cells. The survival of cells was significantly decreased, and number of cells migrating and invading was decreased in the miR-634 mimics group. However, in the miR-634 inhibitor group, the opposite results were observed. Over-expression of miR-634 inhibited the proliferation, migration, and invasion of gastric cancer cell lines, and the miR-634 target gene was JAG1.

Introduction
Gastric cancer is one of the most common malignant tumors, and is a serious threat to human health. Gastric cancer accounts for one-third of cancers worldwide, with nearly 1 million new cases occurring each year [1]. In recent years, although diagnosis and treatment options are progressing, the percentage of early diagnosis of gastric cancer remains low, and most patients first diagnosed with gastric cancer are already in the advanced stage or late stage, with local infiltration and lymph node metastasis. Therefore, the overall prognosis is poor [2]. It is, therefore, urgent to study the mechanism of gastric cancer progression and metastasis, and to seek effective interventions to improve the prognosis of gastric cancer.

The microRNA (miRNA) is a class of noncoding endogenous small RNAs with lengths of about 18–22 nucleic acids. The miRNAs can combine with mRNA at the 3′-untranslated region (UTR), thus playing a role in regulating gene expression at the posttranscriptional level [3]. It has been reported that miRNAs can be used as oncogenes or tumor suppressors to regulate the proliferation, invasion, and metastasis of tumor cells, inhibit angiogenesis and inhibit cell apoptosis [3–6]. It was also reported that hypermethylation of CpG islands in the promoter region of miRNAs is one of the mechanisms of miRNA silencing in tumors [3, 7, 8]. CpG island methylation is tissue and cell specific, is related to...
the occurrence and development of disease, and is involved in the expression of DNA mismatch repair genes [9].

Studies have indicated that miR-634 plays an important role in some cancers. For example, miR-634 inhibited cell growth in breast cancer, but also blocked the HER2 pathway [10]. Research also demonstrated that due to the metabolic effects of miR-634 bicarbonate, it plays an important role in the pathogenesis of obesity [11]. In esophageal squamous cell carcinoma, miR-634 activated the mitochondrial apoptotic pathway and enhanced the cytotoxicity induced by chemotherapy [12]. Overexpression of miR-634 promoted cell apoptosis in ovarian carcinoma, and the expression levels of miR-634 affected the sensitivity to chemotherapeutic drugs. For example, miR-634 enhanced the drug sensitivity to cisplatin, carboplatin, and doxorubicin, but did not enhance chemosensitivity to paclitaxel [13]. In nasopharyngeal carcinoma, miR-634 enhanced the drug sensitivity to paclitaxel and reversed Taxol resistance [14]. However, there is no report regarding the role of miR-634 in gastric cancer. As previously suggested, the different expression levels of miR-634 in different types of cancer are tissue and organ specific. Therefore, we investigated the expression of miR-634 in gastric carcinomas and its effect on the function of gastric cancer cells.

Materials and Methods

The specimens and cell lines

All human gastric cancer cell lines, MGC803, SGC7901, MKN45, HGC27, and the human normal gastric epithelial cell line (GES-1) were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). All patient tumor and adjacent tissues were obtained from the Fourth Affiliated Hospital of China Medical University from January 2014 to January 2016. Patients were treated with radical gastrectomy for gastric cancer in a total of 83 cases. Primary gastric cancer and adjacent tissues were obtained from each patient, and no patient was not treated with radiotherapy and/or chemotherapy before the operation. Some of the resected specimens were stored in liquid nitrogen prior to DNA and RNA extractions. The study was approved by the medical ethics committee of the Fourth Affiliated Hospital of China Medical University, and all patients provided informed consent.

Cell culture and demethylation treatment

The cell culture medium used was RPMI-1640 with 10% fetal bovine serum (Gibco BRL, Grand Island, NY, USA), and the cells were incubated with 5% CO₂ at 37°C. The changes of miR-634 expression in gastric cancer cells were observed by demethylation treatment. The demethylation involved 3 mol/L of 5-aza-2 deoxycytidine (5-aza-d C) added to the cells for 72 h. Dimethyl sulfoxide (DMSO) treatment was used for the control group.

Quantitative real-time (RT) PCR

Trizol™ was used to extract total RNA (Takara, Tokyo, Japan) from cells and tissues. According to the manufacturer’s instructions, cDNA was synthesized by a RevertAid™ First Strand Synthesis Kit (Thermo Fisher, Scotts Valley, CA, USA). U6 was used as a reference, and the cDNA template was placed in an Exicycler™ 96 real-time quantitative fluorescence PCR instrument (Bioneer, Daejeon, Republic of Korea). The reactions were as follows: Hsa-miR-634 forward, 5′-CAGTCTCAAACCAGCACC-3′; reverse, 5′-TATGGTTGTTCAGCAGTCTCAC-3′. The PCR thermal cycle parameters were: 95°C, 5 min, 95°C, 30 sec, 55°C, 30 sec, 72°C, 45 sec, and 35 cycles, 72°C, 5 min. The fluorescence signal was collected and the relative expression of mRNA was calculated by the 2^−ΔΔCT method.

Methylation-specific PCR

MiR-634 gene methylation and non-methylation primers were designed with Methprimer software, and methylation-specific PCR (MSP) detection was performed. The HasmiR-634 gene methylation primers were: upstream, 5′-ATATGTTAGTAGTGGGTTCGA-3′; downstream, 5′-ATATCCAAAAAATAACTTTGTT-3′; non-methylated primers: upstream, 5′-TTATGTTAGTAGTGGGTTCGA-3′; downstream, 5′-ATATCCAAAAAATAACTTTGTT-3′. The PCR reaction conditions were as follows: 95°C, 10 min, 94°C, 45 sec, 56°C, 45 sec, 59°C, 45 sec, 72°C, 45 sec, 35 cycles, 72°C, 10 min. The PCR product (2 μL) was separated by agarose gel electrophoresis, stained with ethidium bromide, and directly observed under UV light. Each sample was tested three times to verify the reproducibility of the experiment.

Lentivirus production and transduction

The construction of the lentivirus vector was performed by GenePharma (Shanghai, China). According to the lentiviral transfection instructions, recombinant miR-634 lentivirus particles, LV-hsa-miR-634-inhibition, and LV-hsa-miR-634, were infected into MGC-803 and SGC-7901 cells, respectively, and a group of cells without any treatment was established as the control group.

Cell wound scratch assay

SGC-7901 and MGC-803 cells transfected with miR-634 mimics and miR-634 inhibitor as well as negative controls
were cultured in six-well plates for 24 h. Then, after using a 200-μL pipette tip to make a scratch line across the cells, the plates were incubated in 5% CO$_2$ at 37°C. Wound healing was observed using an inverted microscope at 0, 24, 48, and 72 h.

**Transwell® migration assay**

After transfection, the cells were adjusted to 1 × 10$^5$ cells/L, with 200 μL of cells placed in each well on the Matrigel™ precoated Transwell® plates in the upper chamber, and with 20% fetal bovine serum and 600 μL of RPMI-1640 cell culture medium in the lower chamber. After 48 h of culturing, the Transwell® membranes were fixed with 4% paraformaldehyde, stained with Crystal Violet for 10 min, and washed with phosphate-buffered saline (PBS) three times. The cells that invaded the membrane were observed under a microscope, and the cell invasion was calculated from randomly photographed areas. The cell invasion percentage = (number of invasive cells in each group/untreated control group) × 100%.

**CCK8 assay**

Cell proliferation was measured by the CCK-8 assay, every 24 h. The cells were seeded into 96-well plates, with 5000 cells per well, 100 μL medium, and 10 μL of the CCK-8 reagent from the kit. Two hours before the assay of each well, 10 μL of CCK-8 reagent was incubated with the cells for 2 h at 37°C. The results were measured using a microplate reader at 450 nm (optical density, OD). The relative proliferation activity = treatment group OD/blank control group OD.

**Plate clone assay**

After infection, the cells were grown to prepare the cell suspension and diluted suspension. The cells were inoculated into six-well plates, with 2 × 10$^3$ cells/well. Each experimental sample used three wells. The cells were cultured for 2–3 weeks. When the cells colonies were visible to the naked eye, the cell culture was terminated, cells were fixed with methanol, Giemsa stained for 10–30 min, and counted under a microscope. The clone formation percentage (%) = clone number/number of inoculated cells × 100%.

**Apoptosis assay**

Gastric cancer cells (1 × 10$^6$ cells) were transfected with miR-634 mimics or inhibitor in six-well plates. After 72 h, the cells were collected, washed, fixed, and permeabilized. Annexin V-FTIC/PI (KeyGen, Nanjing, China) was used to visualize the cells, according to the manufacturer’s instructions, and flow cytometry was used to determine cell apoptosis.

**Luciferase reporter assay**

H-293T, SGC-7901, and MGC-803 cells were seeded into the 24-well plates for 24 h before transfection. The plasmid was constructed by Genomeditech (Shanghai, China). The Renilla reference plasmid, miR-634 control cells, miR-634 mimics cells, and the target gene 3′-UTR reporter gene plasmid were cotransfected. Luciferase activity was measured using a double luciferase gene reporter system after transfection with Lipofectamine® 2000 (Thermo Fisher) for 48 h.

**Western blotting**

RIPA buffer (Vazyme, Nanjing, China) was used to extract total protein. The extraction method was according to the manufacturer’s instructions. Protein concentration was determined using the BCA protein concentration assay kit (Takara, Dalian, China). Thirty micrograms of protein was loaded onto SDS-PAGE gels (Takara) and transferred to a polyvinylidine fluoride membrane (Takara). The membrane was completely immersed in 5% bovine serum albumin (BSA) for 2 h, at room temperature, and the primary antibody was added and incubated at 4°C overnight. The secondary antibody was then added to the membrane and incubated at room temperature for 2 h. The membranes were visualized using a chemiluminescence system.

**Statistical analysis**

All statistical analyses were performed using the SPSS 20.0 software (SPSS Inc., Chicago, IL, USA). The measurement data were expressed by mean ± SD. Pearson’s χ$^2$-test was used to analyse the clinicopathologic features. Survival curves were analyzed by Kaplan–Meier method and compared by the log-rank test. All P values <0.05 were considered statistically significant.

**Results**

**MiR-634 was downregulated in gastric cancer tissues and cells**

The expression levels of miR-634 in the gastric cancer cell lines, HGC-27, MKN-45, SGC-7901, MGC-803, and the normal gastric epithelial cell line, GES-1, were detected by quantitative real-time PCR (qRT-PCR). Compared with the expression of miR-634 in normal gastric epithelial cells (GES-1), the expression of miR-634 was downregulated in gastric cancer cell lines (Fig. 1A). In addition,
expression level of miR-634 in 83 gastric cancer tissues and adjacent tissues was detected by qRT-PCR. The expression level of miR-634 in cancer tissues was significantly lower than that in the adjacent tissues (Fig. 1B). We also analyzed the correlation between the expression level of miR-634 and clinical pathological features. The patients were divided into two groups. The cancer tissues with higher than the median expression of miR-634 were selected as the high group, while those with less than the median expression of miR-634 were selected as the low group. As shown in Table 1, miR-634 expression was downregulated significantly in tumors with diameters >3 cm ($P = 0.029$).

The miR-634 gene was highly methylated in gastric cancer cell lines and cancer tissues

MSP was used to detect the methylation status of gastric cancer and cancer tissues. The expression of miR-634 in gastric cancer cells was relatively low without 5-aza-d C treatment, and 5-aza-d C could reverse the methylation of miR-634 to restore its expression (Fig. 2A). In addition, the gastric cancer cells showed high methylation without 5-aza-d C treatment. After 5-aza-d C treatment, the gastric cancer cell lines showed a low methylation status (Fig. 2B), suggesting that aberrant methylation of the promoter region of the miR-634 gene was an important mechanism leading to its loss of expression in gastric cancer cells. The methylation status of the miR-634 gene in gastric cancer and adjacent tissues was determined by the MSP method. The results showed that the methylation of the miR-634 gene promoter in gastric cancer tissues was significantly higher than that in adjacent tissues (Fig. 2C and D).

MiR-634 inhibited the proliferation, invasion, and migration of gastric cancer cells

In order to study the role of miR-634 in gastric cancer, MGC803 and SGC7901 cells were transfected with miR-634 inhibitors and mimics based on the results of qRT-PCR miR-634 expression in gastric cancer cells. We used qRT-PCR to verify the effects of the transfections (Fig. 3A–D). The effect of miR-634 on the migration ability of gastric cancer cells was detected by wound scratch assays. The healing results were observed at 0, 24, 48, and 72 h. The results showed that MGC-803 and SGC-7901 cells transfected with miR-634 mimics inhibited the migration of gastric cancer cells compared with the control group. However, MGC-803 and SGC-7901 cells transfected with miR-634 inhibitor showed the opposite results (Fig. 4A). The effect of miR-634 on invasion of gastric cancer cells was tested by Transwell® invasion assays. Compared with the control group, MGC-803 and SGC-7901 cells transfected with miR-634 mimics inhibited the invasion of gastric cancer cell lines, whereas MGC-803 and SGC-7901 cells transfected with the miR-634 inhibitor showed the opposite results (Fig. 4B). The effect of miR-634 on proliferation of gastric cancer cells was measured by the CCK8 assay. Compared with the control group, the growth of MGC-803 and SGC-7901 cells transfected with miR-634 mimics was significantly decreased, while the cells transfected with miR-634 inhibitor showed the opposite effects (Fig. 5A). Clone formation assays showed that overexpression of miR-634 inhibited the proliferation of gastric cancer cells, and knockdown of miR-634 reversed these effects (Fig. 5B).

The annexin V-FITC apoptosis detection kit was used to analyze the impact of miR-634 on the function of early gastric cancer cell apoptosis. The results showed that compared with the control group, MGC-803 and SGC-7901 cells transfected with miR-634 mimics showed induced apoptosis in gastric cancer cells. However, MGC-803 and SGC7901 cells transfected with miR-634 inhibitors showed the opposite effects (Fig. 5C). In addition, western blot results showed that the expression of phenotype-associated markers was altered by transfection of miR-634 mimics or inhibitors. MiR-634 induction increased the level of

Figure 1. MiR-634 was downregulated in gastric cancer (GC) tissues and cells. (A) The expression levels of miR-634 in GC cells and GES-1 cells. (B) The expression levels of miR-634 in 83 pairs of human GC tissues and adjacent normal tissues measured by quantitative real-time PCR (qRT-PCR). *, $P < 0.05$
Expression of miR-634 in Gastric Carcinoma

J. Guo et al.

the epithelial marker E-cadherin and suppressed the levels of the proliferation associated markers cyclinD1 and ki-67. In contrast, miR-634 inhibition had the complete opposite effect (Fig. 8C and F). Taken together, the results showed that overexpression of miR-634 inhibited the proliferation of gastric cancer cells in vitro. Overexpression of miR-634 may therefore play an important role in the migration and invasion of gastric cancer cells.

Table 1. Expression of miRNA-634 and JAG1 in human gastric cancer according to patients’ clinicopathological characteristics. *, P < 0.05

| Characteristics          | Number (%) | miR-634 expression | JAG1 expression |
|--------------------------|------------|--------------------|-----------------|
|                          |            | Low group | High group | P-value | Low group | High group | P-value |
| Age (years)              |            |           |           |         |           |           |         |
| <60                      | 32         | 15        | 17        | 0.498   | 12        | 20        | 0.496   |
| ≥60                      | 51         | 29        | 22        |          | 24        | 27        |          |
| Gender                   |            |           |           |         |           |           |         |
| Male                     | 64         | 34        | 30        | 1.000   | 27        | 37        | 0.794   |
| Female                   | 19         | 10        | 9         |          | 9         | 10        |          |
| Size (cm)                |            |           |           |         |           |           |         |
| <3                       | 38         | 15        | 23        | 0.029*  | 11        | 27        | 0.026*  |
| ≥3                       | 45         | 29        | 16        |          | 25        | 20        |          |
| Histology grade          |            |           |           |         |           |           |         |
| Well-modestly            | 25         | 12        | 13        | 0.634   | 12        | 13        | 0.634   |
| Poorly-signet            | 58         | 32        | 26        |          | 24        | 34        |          |
| Stage                    |            |           |           |         |           |           |         |
| I/II                     | 28         | 13        | 15        | 0.487   | 12        | 16        | 1.000   |
| III/IV                   | 55         | 31        | 24        |          | 24        | 31        |          |
| T grade                  |            |           |           |         |           |           |         |
| T1 + T2                  | 27         | 17        | 10        | 0.246   | 11        | 16        | 0.815   |
| T3 + T4                  | 56         | 27        | 29        |          | 25        | 31        |          |
| Lymph node metastasis    |            |           |           |         |           |           |         |
| Absent (N0)              | 31         | 17        | 14        | 0.824   | 15        | 16        | 0.501   |
| Present (N1–N3)          | 52         | 27        | 25        |          | 21        | 31        |          |

Figure 2. The miR-634 gene was highly methylated in gastric cancer cell lines and cancer tissues. (A) Quantitative real-time PCR (qRT-PCR) was used to detect the expression of the miR-634 gene in gastric cancer (GC) cell lines treated or untreated with 5-aza-2'-deoxycytidine (5-aza-dC). (B) The methylation-specific PCR (MSP) method was used to detect the methylation status of the miR-634 gene in gastric cancer cell lines treated or untreated with 5-aza-dC. −, 5-aza-dC untreated; +, 5-aza-dC treated. (C and D) The relationships between methylation status and expression of miR-634 in GC tumor tissues. *, P < 0.05
High expression of JAG1 in gastric cancer tissues and cells

In order to measure the expression of JAG1 in gastric cancer, we analyzed the expression of JAG1 in 83 pairs of human gastric cancer and para cancer specimens by qRT-PCR. The expression level of JAG1 in gastric carcinoma was upregulated (Fig. 6A), which expression was inversely correlated with miR-634 in gastric cancer (Fig. 6B). The expression levels of JAG1 in gastric cancer cell lines and the GES-1 cell line were measured by qRT-PCR and western blot methods. The results showed that JAG1 expression was higher in gastric cancer cell lines compared with the levels in the GES-1 cell line, as shown in Figure 6C and D. Next, we detected the expression level of JAG1 protein in six gastric cancer tissues by western blotting. As shown in Figure 6E, the levels of JAG1 protein in gastric cancer tissues were higher than that in adjacent tissues. We also evaluated the clinicopathological features of JAG1. In the gastric cancer tissues, the expression of JAG1 below the median value was selected into low group, while those above the median value was selected into high group. There is no significant association was observed between JAG1 expression and age ($P = 0.496$), gender ($P = 0.794$), or stage ($P = 1.000$). However, its expression was significantly correlated with tumour size ($P = 0.026$). As shown in Table 1, the expression level of JAG1 was up-regulated in the tumor size larger than 3 cm group.

JAG1 is a direct target of miR-634

MiRNA target prediction sites (miRDB, TargetScan, and miRanda) predicted that JAG1 may be the target gene of miR-634 (Fig. 7A). The target gene of miR-634 was verified by luciferase assays. First, miR-634 regulation of JAG1 transcription was demonstrated in 293 cells. Then, in order to further verify the regulatory effect of miR-634 on JAG1, MGC-803 and SGC-7901 cells were selected, and the results shown in Fig. 7B suggested that the downstream target of miR-634 was JAG1. In addition, qRT-PCR and western blot showed the decreased JAG1 expression after transfection with miR-634 mimics in MGC-803 and SGC-7901 cells (Fig. 8B–F). Moreover, suppression of miR-634 enhanced the level of JAG1 in the above cells (Fig. 8A, D–F).

Prognosis of miR-634 and JAG1 in gastric carcinoma

The recurrence free survival (RFS) was defined as the time from surgery to recurrence or death of any other causes. The overall survival (OS) was defined as the time from operation to death. In the OS analysis, median survival time was 41 months in GC patients with high miR-634 expression, which was longer than in patients with low miR-634 expression (31 months, $P = 0.038$; Fig. 9A). Furthermore, the survival curve showed that the survival time of the elevated JAG1 expression group was lower...
Figure 4. MiR-634 suppresses cell migration and invasion in gastric cancer. (A) Wounds were created in MGC-803 and SGC-7901 cells after transfection with miR-634 inhibitor and miR-634 lentivirus mimics. (B) The Transwell® invasion assay was used in gastric cancer cells transfected with miR-634 inhibitor and miR-634 lentivirus mimics. *, P < 0.05
than that of the JAG1 low expression group, even though there was no statistically difference between them ($P = 0.655$; Fig. 9C). Recurrence was compared between the elevated miR-634 and miR-634 low group in 83 patients. The median follow-up duration was 28 months (range: 4–42 months). In the RFS analysis, the elevated miR-634 showed a lower recurrence rate than the miR-634-low group ($P = 0.012$, Fig. 9B). However, there was no difference in RFS between the elevated JAG1 and JAG1-low groups ($P = 0.586$, Fig. 9D). These findings suggest that miR-634 expression might better serve as a prognostic biomarker in GC.

**Discussion**

Gastric cancer is one of the most common cancers in the world. Although the treatment of gastric cancer is improving, the treatment of advanced gastric cancer is still not effective. In the past, some reports have suggested that miRNA is a marker of gastric cancer [4, 15]. Recent reports have indicated that miRNA can be used as a tumor promoter or as a tumor suppressor, depending on the type of cancer and its target gene [16, 17]. For example, in gastric cancer cell lines, miR-137 played a role in tumor suppression by KLF12 and MYO1C [18]. Abnormal expression of miR-27b inhibited the proliferation of gastric cancer cells [19]. MiR-187 promoted the growth and metastasis of gastric cancer cells by targeting FOXA2 in gastric cancer [16]. Further studies have found that a large proportion of the miRNA genes are located close to CpG islands. Therefore, the change of miRNA gene expression may be due to epigenetic regulatory mechanisms, especially the aberrant methylation of CpG islands [20]. For example, methylation of the miR-375 promoter CpG island in esophageal cancer cells led to low expression of miR-375. However, there was no methylation in normal mucosa [21].

The mechanism of miR-634 in the carcinogenesis and progression of gastric cancer remains unclear. The purpose of this study was therefore to investigate the expression of miR-634 in gastric carcinoma and its effects on the function of gastric cancer cells. We found that miR-634 was downregulated in gastric cancer cell lines and gastric cancer tissues. Clinical data showed that the downregulation of miR-634 was related to tumor size, and the more miR-634 expression was downregulated, the larger the...
tumor volume. Using the online software, Methly Primer, to predict the presence of two CpG islands in the promoter region of miR-634 gene, it was further speculated that the downregulation of miR-634 gene expression may be closely related to the hypermethylation of the promoter region of the gene. The methylation status of the miR-634 gene in gastric cancer cell lines was detected by the MSP method for the first time. The expression level of the miR-634 gene in gastric cancer cell lines without 5-aza-dC treatment was relatively low, and at the same time,
Figure 8. The JAG1 expression in cells transfected with miR-634 inhibitor and miR-634 mimics lentivirus. (A-B) The expression of JAG1 in GC cell lines derived from MGC-803 cells was determined by quantitative PCR after transfection of miR-634 inhibitor or mimics lentivirus. (C) The expression of JAG1, E-cadherin, and cyclinD1 were detected by western blotting at 48 h after transfection in MGC-803 cells. (D and E) Quantitative results of JAG1 after transfection of miR-634 inhibitor or mimics lentivirus in SGC-7901 cells, with miR-634 NC as control. (F) The JAG1, E-cadherin, cyclinD1 and Ki-67 protein levels were detected in SGC-7901 cells by western blotting in cells transfected with miR-634 inhibitor or mimics lentivirus. *, P < 0.05

Figure 9. (A) The survival curve for OS of GC patients with different miR-634 expression levels (P = 0.038). (B) The survival curve for RFS of GC patients with different miR-634 expression levels (P = 0.012). (C) The survival curve for OS of GC patients with different JAG1 expression levels (P = 0.655). (D) The survival curve for RFS of GC patients with different JAG1 expression levels (P = 0.586).
the untreated gastric cancer cell lines showed a high methylation status. After 5-aza-dC treatment, the expression of the miR-634 gene in gastric cancer cell lines increased, and the extent of methylation decreased. The results suggested that DNA methylation may be one of the main mechanisms of downregulation of miR-634 gene expression in gastric cancer. We also detected the methylation status of miR-634 in 83 gastric cancer tissues and corresponding adjacent tissues. The methylation percentage was significantly higher than that in the corresponding adjacent tissues; also suggesting that miR-634 gene expression may be related to the abnormal gene promoter methylation. In addition, studies have shown that miR-634 expression was downregulated in osteoarthritic chondrocytes [22], hepatocellular carcinoma [23], cervical cancer [24], prostate cancer [25], and ovarian cancer [13], and the expression levels of miR-634 were consistent with our findings. We further examined the effects of miR-634 on gastric cancer cells, and the results showed that overexpression of miR-634 inhibited gastric cancer cell proliferation, migration, invasion, and apoptosis, and silencing of miR-634 had the opposite effect. Survival analysis showed that although the survival rate of target genes was no statistical significance, the high expression of miR-634 could lead to longer survival time and lower recurrence rate. However, the trend of survival in the high expression group was lower than that in the low expression group. Taken together, we reached the conclusion that miR-634 functioned as anti-oncogene and suppressed the progression of gastric cancer.

The binding site of JAG1 indicates that it is a potential target gene of miR-634. JAGGED1 (JAG1) on chromosome 20, cytogenetic location 20p12.2, chr20:10618331-10654693, genome mapping (grch37), contains 26 exons of more than 36 kB, and codes for a protein of 1218 amino acids [26]. The first discovery of JAG1 associated with cancer was reported in 2005. The study confirmed that the expression of JAG1 is upregulated in human breast cancer and is associated with a poorer overall survival rate in a dose-dependent manner [27]. Our study found an inverse relationship between miR-634 and JAG1 expression. High expression of miR-634 inhibited the expression of JAG1, but low expression of miR-634 promoted the high expression of JAG1. In addition, the high expression of JAG1 was associated with the formation of tumor-associated angiogenesis in brain and ovarian cancer [28, 29].

There are several limitations in this study. First, the mechanism of JAG1 in gastric cancer is not clear, the role and significance of it in signaling pathway will be further studied. Second, as our collection of samples is limited, it may not adequately reflect overall prognostic characteristics. Third, the follow-up time was short. Accordingly, we will need a large sample study and a longer follow-up to verify our results in the future.

In conclusion, this study suggested that aberrant hypermethylation of CpG islands in the promoter region was one of the important mechanisms leading to decreased expression of miR-634 in gastric cancer. These results provided novel treatment strategies for gastric cancer by modifying the methylation status of the miR-634 gene. Through JAG1, miR-634 can downregulate the expression of JAG1 mRNA. Moreover, this study suggested that miR-634 is a useful biomarker for early detection of gastric cancer that could improve our understanding of the role of miRNAs in the pathogenesis of gastric cancer and its early diagnosis. In the future, we plan to study the inhibitory mechanism of miR-634 in gastric cancer to improve early diagnosis and treatment of this disease.

**Acknowledgments**

None.

**Conflict of Interest**

All authors declare no conflict of interest.

**References**

1. Torre, L. A., F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal. 2015. Global cancer statistics, 2012. CA Cancer J. Clin. 65:87–108.
2. Jou, E., and L. Rajdev. 2016. Current and emerging therapies in unresectable and recurrent gastric cancer. World J. Gastroenterol. 22:4812–4823.
3. Zhang, J. K., Y. S. Li, C. D. Zhang, D. Q. Dai. 2017. Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer. Cancer Cell Int. 17:28.
4. Chen, P., W. Xu, Y. Luo, Y. Zhang, Y. He, S. Yang, et al. 2017. MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK. Onco. Targets Ther. 10:1423–1431.
5. Huang, L., F. Li, P. Deng, C. Hu. 2016. MicroRNA-223 promotes tumor progression in lung cancer A549 cells via activation of the NF-kappaB signaling pathway. Oncol. Res. 24:405–413.
6. Pan, C., D. Wang, Y. Zhang, W. Yu. 2016. MicroRNA-1284 inhibits cell viability and induces apoptosis of ovarian cancer cell line OVCAR3. Oncol. Res. 24:429–435.
7. Ramalho-Carvalho, J., J. B. Martins, L. Cekaite, A. Sveen, J. Torres-Ferreira, I. Graça, et al. 2017. Epigenetic disruption of miR-130a promotes prostate...
cancer by targeting SEC23B and DEPDC1. Cancer Lett. 385:150–159.
8. Zhang, J., J. Fu, Y. Pan, X. Zhang, L. Shen. 2016. Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1. Onco. Targets Ther. 9:7297–7307.
9. Lai, Y., Z. Jiang, J. Zhou, E. Osemota, and Y. Liu. 2016. AP endonuclease 1 prevents the extension of a T/G mismatch by DNA polymerase beta to prevent mutations in CpGs during base excision repair. DNA Repair (Amst.) 43:89–97.
10. Leivonen, S. K., K. K. Sahlberg, R. Makela, E. U. Due, O. Kallioniemli, A. L. Børresen-Dale, et al. 2014. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol. Oncol. 8:93–104.
11. Li, J., C. Zhou, J. Li, Z. Su, H. Sang, E. Jia, et al. 2015. Global correlation analysis for microRNA and gene expression profiles in human obesity. Pathol. Res. Pract. 211:361–368.
12. Fujiwara, N., J. Inoue, T. Kawano, K. Tanimoto, K. Kozaki, J. Inazawa. 2015. miR-634 activates the mitochondrial apoptosis pathway and enhances chemotherapy-induced cytotoxicity. Cancer Res. 75:3890–3901.
13. van Jaarsveld, M. T., P. F. van Kuijk, A. W. Boersma, J. Helleman, R. H. Mathijsen, E. M. Berns, et al. 2015. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras- MAPK pathway. Mol. Cancer. 14:196.
14. Peng, X., P. Cao, D. He, S. Han, J. Zhou, G. Tan, et al. 2014. MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int. J. Clin. Exp. Pathol. 7:6784–6791.
15. Liu, H. T., Y. W. Wang, A. Y. Xing, D. B. Shi, H. Zhang, X. Y. Guo, et al. 2017. Prognostic value of microRNA signature in patients with gastric cancers. Sci. Rep. 7:42806.
16. Li, C., S. Lu, and Y. Shi. 2017. MicroRNA-187 promotes growth and metastasis of gastric cancer by inhibiting FOXA2. Oncol. Rep. 37:1747–1755.
17. Oliveto, S., M. Mancino, N. Manfrini, S. Biffo. 2017. Role of microRNAs in translation regulation and cancer. World J. Biol. Chem. 8:45–56.
18. Du, Y., Y. Chen, F. Wang, L. Gu. 2016. miR-137 plays tumor suppressor roles in gastric cancer cell lines by targeting KLF12 and MYO1C. Tumour Biol. 37:13557–13569.
19. Geng, Y., X. Lu, X. Wu, L. Xue, X. Wang, J. Xu. 2016. MicroRNA-27b suppresses Helicobacter pylori-induced gastric tumorigenesis through negatively regulating Frizzled7. Oncol. Rep. 35:2441–2450.
20. Pronina, I. V., V. I. Loginov, A. M. Burdennyy, M. V. Fridman, V. N. Senchenko, T. P. Kazubskaya, et al. 2017. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. Gene 604:1–8.
21. Li, X., R. Lin, and J. Li. 2011. Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig. Dis. Sci. 56:2849–2856.
22. Cui, X., S. Wang, H. Cai, Y. Lin, X. Zheng, B. Zhang, et al. 2016. Overexpression of miRNA-634 suppresses survival and matrix synthesis of human osteoarthritis chondrocytes by targeting PIK3R1. Sci. Rep. 6:23117.
23. Zhang, C. Z., Y. Cao, J. Fu, J. P. Yun, M. F. Zhang. 2016. miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33. Mol. Oncol. 10:1532–1541.
24. Cong, J., R. Liu, X. Wang, H. Jiang, Y. Zhang. 2016. MiR-634 decreases cell proliferation and induces apoptosis by targeting mTOR signaling pathway in cervical cancer cells. Artif. Cells Nanomed. Biotechnol. 44:1694–1701.
25. Ostling, P., S. K. Leivonen, A. Aakula, P. Kohonen, R. Mäkelä, Z. Hagman, et al. 2011. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 71:1956–1967.
26. Oda, T., A. G. Elkahloun, P. S. Meltzer, and S. C. Chandrasekharappa. 1997. Identification and cloning of the human homolog (JAG1) of the rat Jagged1 gene from the Alagille syndrome critical region at 20p12. Genomics 43:376–379.
27. Reedijk, M., S. Odorcic, L. Chang, H. Zhang, N. Miller, D. R. McCready, et al. 2005. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 65:8530–8537.
28. Lu, C., T. Bonome, Y. Li, A. A. Kamat, L. Y. Han, R. Schmandt, et al. 2007. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 67:1757–1768.